Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
Details : FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3. FS118 is designed to provide unique pharmacology, that drives PD-L1 dependent LAG-3 shedding and receptor down-regulation, via bispecific activity, and potentially offering a more durable re...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $161.0 million
August 03, 2023
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 22, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $41.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ pl...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $1.0 million
July 20, 2022
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $41.0 million
Deal Type : Licensing Agreement
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FS118 is a first-in-class tetravalent bispecific antibody binding to LAG-3 and PD-L1, resulting in the reversal of immune suppression. FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
Details : F-star’s unique next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharm’s existing capabilities and reinforces its global oncology pipeline including FS118.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $161.0 million
June 23, 2022
Lead Product(s) : FS118,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
Details : FS222 targets critical tumoral immune-suppressing pathways via PD-L1 checkpoint blockade and exhibited important costimulatory effect of potent clustering and activation of CD137, which in turn, promotes T cell activation and enhanced cytotoxic T cell re...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $1,367.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, F-star will grant Janssen, a exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ a...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $17.5 million
October 20, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $1,367.5 million
Deal Type : Licensing Agreement
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
Details : FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist used in patients with advanced malignancies. Safety and PK/PD data trigger initiation of the previously announced FS120 and KEYTRUDA® (pembrolizumab) combination study, scheduled to...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $312.0 million
Deal Type : Licensing Agreement
Details : AstraZeneca will be responsible for all future research, development and commercialization of the STING inhibitor compounds, and F-star will retain rights to all STING agonists, currently in clinical development for patients with cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $12.0 million
August 07, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $312.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $312.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AstraZeneca is granted exclusive access to F-star’s novel preclinical next generation Stimulator of Interferon Genes (STING) inhibitor compounds for its research, development and commercialization.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $12.0 million
August 07, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $312.0 million
Deal Type : Licensing Agreement